Lung Cancer

Paclitaxel/carboplatin/etoposide compared to paclitaxel/topotecan

Published in Clinical Oncology Week, January 9th, 2006

The paclitaxel/carboplatin/etoposide chemotherapy regimen was compared to paclitaxel/topotecan regimen in extensive-stage small cell lung cancer.

Researchers in the United States conducted a study "to compare the combination of paclitaxel (Taxol) and topotecan (Hycamtin) with paclitaxel, carboplatin (Paraplatin; Bristol-Myers Squibb), and etoposide (Etopophos, VePesid) in patients with previously untreated extensive-stage small cell lung cancer."

"In this phase II trial, 120 patients were randomly allocated to receive either topotecan (1.5 mg/m² i.v. days 1, 2, and 3) and paclitaxel (175 mg/m² i.v.day 1) every 21 days or...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Clinical Oncology Week

Source: Clinical Oncology Week (2006-01-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry